de la Fuente-Nunez is a presidential associate professor at the University of Pennsylvania. Skinner is CEO of the AMR Action Fund. Of all the areas of drug development that artificial intelligence has ...

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug ...

DUBLIN, CA, UNITED STATES, March 31, 2026 /EINPresswire.com/ -- Through transformative approaches to drug development, ...

HANGZHOU, ZHENJIANG, CHINA, April 1, 2026 /EINPresswire.com/ -- The global medical community has observed a significant ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

Antibiotics have been a cornerstone of modern medicine, saving countless lives since their discovery. However, the world is now facing an alarming rise in antibiotic-resistant bacteria, which ...

Antibiotics are a crucial tool in the fight against bacterial infections. But the World Health Organization has long warned that we are facing an antibiotic crisis. Bacteria can easily adapt, evolve, ...

HSSA Funding to Support Commercialization of Biological Testing Platform and High-Paying Bioscience Jobs in Spokane ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Early-stage drug development worldwide has nearly doubled over the past decade and shifted from a U.S.-dominated model to a ...

Although the past decade has been marked by lack of innovation in the field of antibiotics development, that trend is changing, according to data from Reportlinker. According to the data, 109 ...

DENVER The last time a new tuberculosis drug was developed, Richard Nixon was in the White House. That drug, Rifampin, "was the biggest thing to hit TB in 30 years," said Dr. Michael Iseman, a ...